ABT as reported
Abbott Laboratories reported $45.1B of revenue over the trailing twelve months, +6.6% on the year before. 11 reported series are charted on this page, each one as filed.
$45.1B
Revenue, trailing twelve months · to Q1 2026 · +6.6% against the twelve months before
- Net Income
- $6.28B
Net Income · −54% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $7.38B
Free Cash Flow · +11% year on year · trailing twelve months to Q1 2026
- Op Margin
- 17%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $45.1B | +6.6% | Q1 2026 |
| Net Income | $6.28B | −54% | Q1 2026 |
| EPS | $3.58 | −54% | Q1 2026 |
| Gross Margin | 56% | n/a | Q1 2026 |
| Op Margin | 17% | n/a | Q1 2026 |
| Net Margin | 14% | n/a | Q1 2026 |
| ROE | 20% | n/a | Q1 2026 |
| ROA | 12% | n/a | Q1 2026 |
| ROIC | 10% | n/a | Q1 2026 |
| Free Cash Flow | $7.38B | +11% | Q1 2026 |
| P/E | 31.9 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Abbott Laboratories (ABT) - Revenue & ProfitRevenue & ProfitAbbott Laboratories (ABT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Devices
Ranks #16 of 35 by Smart Score